Skip to main content

Tepotinib Pregnancy and Breastfeeding Warnings

Medically reviewed by Drugs.com. Last updated on Apr 16, 2021.

Tepotinib is also known as: Tepmetko

Tepotinib Pregnancy Warnings

Animal studies have revealed evidence of malformations (teratogenicity) and anomalies at exposures lower than human exposures. After pregnant rabbits received oral doses during organogenesis, severe maternal toxicity was observed at 450 mg/kg (about 0.75 times the human exposure at the 450 mg clinical dose); at 150 mg/kg (about 0.5 times the human exposure by AUC at the clinical dose), 2 animals aborted, 1 died prematurely, and mean fetal body weight decreased. A dose-dependent increase of skeletal malformations occurred at doses at least 5 mg/kg (about 0.003 times the human exposure by AUC at the clinical dose), and a case of spina bifida was seen at 5 mg/kg. There are no controlled data in human pregnancy.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Use is not recommended unless clearly needed.

US FDA pregnancy category: Not assigned.

Risk summary: Based on animal studies and its mechanism of action, this drug can cause fetal harm.

Comments:
-Pregnant women, women of childbearing potential, and male patients with female partners of childbearing potential should be apprised of the potential harm to the fetus.
-Pregnancy testing is recommended in women of childbearing potential before starting this drug; according to some authorities, pregnancy status should be verified is such patients before starting therapy.
-Females of childbearing potential and male patients with female partners of childbearing potential should be advised to use effective contraception during therapy and for 1 week after the last dose.

See references

Tepotinib Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug and for 1 week after the last dose.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments:
-No information is available on the clinical use of this drug during breastfeeding.
-Because this drug is highly bound to plasma proteins, the amount in milk is likely to be low; however, it is potentially toxic in the breastfed infant and has a half-life of 32 hours.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Tepmetko (tepotinib)." EMD Serono Inc (2021):

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Tepmetko (tepotinib)." EMD Serono Inc (2021):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.